跳至主要内容
临床试验/JPRN-UMIN000003453
JPRN-UMIN000003453已完成2 期

Phase II study of alternate-day administrations of S-1 as 1st-line treatment in patients with metastatic and locally advanced pancreatic cancer - Phase II study of alternate-day administrations of S-1 as 1st-line treatment in patients with metastatic and locally advanced pancreatic cancer

Pancreatic Cancer Treatment Research Group0 个研究点目标入组 45 人开始时间: 2010年4月6日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
45

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Symptomatic pulmonary fibrosis or interstitial pneumonia 2)Severe diarrhea 3)Active infection 4)Severe complications, such as ileus, heart failure and renal failure 5)Marked pleural or peritoneal effusion 6)Metastasis in central nervous system 7)Active double cancer 8)Patients under treatment with flucytosine, phenytoin or warfarin potassium 9)Pregnant females, possibly pregnant females, females wishing to become pregnant and nursing mothers. Males that are currently attempting to produce a pregnancy 10)Severe mental disorder 11)History of severe anaphylaxies 12)Inadequate physical condition, as diagnosed by primary physician

研究者

发起方
Pancreatic Cancer Treatment Research Group

相似试验